Economic benefit of prescribing an adjusted renal dose of dipeptidyl peptidase IV inhibitors in type 2 diabetes patients with chronic kidney disease.
Sun Joon MoonYoung Min ChoPublished in: Journal of diabetes (2020)
Highlights Based on nationwide insurance data in Korea, the use of dipeptidyl peptidase IV inhibitors (DPP-IVi) not requiring renal dose adjustment (NRDA DPP-IVi) is widespread in the type 2 diabetes chronic kidney disease (T2D CKD) population. Instead of prescribing NRDA DPP-IVi, the use of DPP-IVi requiring renal dose adjustment with appropriate renal dose adjustments in T2D CKD patients can achieve a considerable annual cost saving of up to 7.8%.
Keyphrases
- chronic kidney disease
- end stage renal disease
- type diabetes
- primary care
- cardiovascular disease
- peritoneal dialysis
- ejection fraction
- newly diagnosed
- glycemic control
- healthcare
- insulin resistance
- metabolic syndrome
- emergency department
- prognostic factors
- machine learning
- artificial intelligence
- cross sectional
- patient reported